nodes	percent_of_prediction	percent_of_DWPC	metapath
Milnacipran—Levomilnacipran—CYP2D6—breast cancer	0.00255	0.267	CrCbGaD
Milnacipran—Levomilnacipran—CYP3A4—breast cancer	0.00218	0.229	CrCbGaD
Milnacipran—Levomilnacipran—ABCB1—breast cancer	0.00182	0.191	CrCbGaD
Milnacipran—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A10—breast cancer	0.00139	0.0241	CbGpPWpGaD
Milnacipran—SLC6A4—Monoamine Transport—ACHE—breast cancer	0.00138	0.024	CbGpPWpGaD
Milnacipran—SLC6A2—Monoamine Transport—ACHE—breast cancer	0.00119	0.0206	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—SLC2A10—breast cancer	0.00116	0.0202	CbGpPWpGaD
Milnacipran—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A7—breast cancer	0.00115	0.02	CbGpPWpGaD
Milnacipran—Pethidine—CYP2D6—breast cancer	0.00115	0.12	CrCbGaD
Milnacipran—SLC6A4—Serotonin Transporter Activity—IL1B—breast cancer	0.00108	0.0188	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—ALDH3A1—breast cancer	0.00108	0.0188	CbGpPWpGaD
Milnacipran—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A18—breast cancer	0.00105	0.0183	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—DLX2—breast cancer	0.00103	0.0178	CbGpPWpGaD
Milnacipran—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A5—breast cancer	0.00101	0.0176	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—SLC2A10—breast cancer	0.001	0.0174	CbGpPWpGaD
Milnacipran—Pethidine—CYP3A4—breast cancer	0.000985	0.103	CrCbGaD
Milnacipran—SLC6A4—Circadian rythm related genes—PER3—breast cancer	0.000984	0.0171	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—SLC39A7—breast cancer	0.000963	0.0167	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—ALDH3A1—breast cancer	0.000929	0.0162	CbGpPWpGaD
Milnacipran—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—breast cancer	0.000871	0.0151	CbGpPWpGaD
Milnacipran—Pethidine—ALB—breast cancer	0.000859	0.09	CrCbGaD
Milnacipran—SLC6A4—NRF2 pathway—SLC2A5—breast cancer	0.000848	0.0147	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—NR2F6—breast cancer	0.000837	0.0145	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—SLC39A7—breast cancer	0.000828	0.0144	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—SLC39A6—breast cancer	0.00073	0.0127	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—SLC2A5—breast cancer	0.000729	0.0127	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—YBX1—breast cancer	0.000692	0.012	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—HADHB—breast cancer	0.000692	0.012	CbGpPWpGaD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC28A1—breast cancer	0.000689	0.012	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—CLDN4—breast cancer	0.000682	0.0119	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—ATF4—breast cancer	0.000682	0.0119	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—THRB—breast cancer	0.000661	0.0115	CbGpPWpGaD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC4A7—breast cancer	0.00063	0.0109	CbGpPWpGaD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC2A10—breast cancer	0.00063	0.0109	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—SLC39A6—breast cancer	0.000628	0.0109	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—GSTA3—breast cancer	0.000621	0.0108	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—PPARGC1B—breast cancer	0.00057	0.00991	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—GSTA4—breast cancer	0.000568	0.00987	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—GSTA2—breast cancer	0.000553	0.00962	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—GPX2—breast cancer	0.000553	0.00962	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—NRIP1—breast cancer	0.000539	0.00937	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—GSTA1—breast cancer	0.000534	0.00928	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—GSTA3—breast cancer	0.000534	0.00928	CbGpPWpGaD
Milnacipran—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A2—breast cancer	0.000524	0.0091	CbGpPWpGaD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC39A7—breast cancer	0.000522	0.00907	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—GSTA4—breast cancer	0.000488	0.00848	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—FOXM1—breast cancer	0.00048	0.00834	CbGpPWpGaD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC22A18—breast cancer	0.000477	0.0083	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—GSTA2—breast cancer	0.000476	0.00827	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—GPX2—breast cancer	0.000476	0.00827	CbGpPWpGaD
Milnacipran—SLC6A4—Monoamine Transport—IL1B—breast cancer	0.000461	0.008	CbGpPWpGaD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC2A5—breast cancer	0.00046	0.00799	CbGpPWpGaD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLCO1B1—breast cancer	0.00046	0.00799	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—GSTA1—breast cancer	0.000459	0.00798	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—SLC2A2—breast cancer	0.000439	0.00763	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—ALDOA—breast cancer	0.000432	0.00751	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—CPT1A—breast cancer	0.000408	0.00709	CbGpPWpGaD
Milnacipran—SLC6A2—Monoamine Transport—IL1B—breast cancer	0.000396	0.00688	CbGpPWpGaD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC39A6—breast cancer	0.000396	0.00688	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—TGFB2—breast cancer	0.000384	0.00666	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—SLC2A2—breast cancer	0.000378	0.00656	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—AHR—breast cancer	0.000374	0.0065	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—SQSTM1—breast cancer	0.000363	0.0063	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—GATA3—breast cancer	0.000357	0.0062	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—SLC5A5—breast cancer	0.000352	0.00612	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC28A1—breast cancer	0.00035	0.00608	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—NQO1—breast cancer	0.00034	0.00591	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—SLC2A1—breast cancer	0.00034	0.00591	CbGpPWpGaD
Milnacipran—SLC6A4—Monoamine Transport—TNF—breast cancer	0.000334	0.00581	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—CPT1A—breast cancer	0.000333	0.00579	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—TGFB2—breast cancer	0.00033	0.00573	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—ESR2—breast cancer	0.00032	0.00556	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC2A10—breast cancer	0.00032	0.00556	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC4A7—breast cancer	0.00032	0.00556	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—HSP90AA1—breast cancer	0.00032	0.00556	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—EGR1—breast cancer	0.000316	0.00549	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—SQSTM1—breast cancer	0.000312	0.00542	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—SLC5A5—breast cancer	0.000303	0.00526	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—EGR1—breast cancer	0.0003	0.00521	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—TOP2A—breast cancer	0.000297	0.00516	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—NQO1—breast cancer	0.000292	0.00508	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—SLC2A1—breast cancer	0.000292	0.00508	CbGpPWpGaD
Milnacipran—SLC6A2—Monoamine Transport—TNF—breast cancer	0.000287	0.00499	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—NCOA2—breast cancer	0.000286	0.00497	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—GSTP1—breast cancer	0.000284	0.00493	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—TGFBR2—breast cancer	0.000284	0.00493	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—AR—breast cancer	0.000283	0.00492	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—EZH2—breast cancer	0.000282	0.0049	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—HMOX1—breast cancer	0.00028	0.00486	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—HSP90AA1—breast cancer	0.000275	0.00478	CbGpPWpGaD
Milnacipran—Tachycardia—Capecitabine—breast cancer	0.000274	0.000293	CcSEcCtD
Milnacipran—Hypoaesthesia—Epirubicin—breast cancer	0.000273	0.000293	CcSEcCtD
Milnacipran—Cardiac disorder—Methotrexate—breast cancer	0.000273	0.000292	CcSEcCtD
Milnacipran—Skin disorder—Capecitabine—breast cancer	0.000272	0.000292	CcSEcCtD
Milnacipran—SLC6A2—NRF2 pathway—EGR1—breast cancer	0.000272	0.00472	CbGpPWpGaD
Milnacipran—Urinary tract disorder—Epirubicin—breast cancer	0.000271	0.000291	CcSEcCtD
Milnacipran—Urticaria—Paclitaxel—breast cancer	0.000271	0.000291	CcSEcCtD
Milnacipran—Hyperhidrosis—Capecitabine—breast cancer	0.000271	0.00029	CcSEcCtD
Milnacipran—Oedema peripheral—Epirubicin—breast cancer	0.000271	0.00029	CcSEcCtD
Milnacipran—Hypotension—Docetaxel—breast cancer	0.000271	0.00029	CcSEcCtD
Milnacipran—Haematuria—Doxorubicin—breast cancer	0.00027	0.00029	CcSEcCtD
Milnacipran—Connective tissue disorder—Epirubicin—breast cancer	0.00027	0.00029	CcSEcCtD
Milnacipran—Abdominal pain—Paclitaxel—breast cancer	0.00027	0.000289	CcSEcCtD
Milnacipran—Body temperature increased—Paclitaxel—breast cancer	0.00027	0.000289	CcSEcCtD
Milnacipran—Urethral disorder—Epirubicin—breast cancer	0.000269	0.000289	CcSEcCtD
Milnacipran—Hepatobiliary disease—Doxorubicin—breast cancer	0.000268	0.000287	CcSEcCtD
Milnacipran—Anorexia—Capecitabine—breast cancer	0.000267	0.000286	CcSEcCtD
Milnacipran—Angiopathy—Methotrexate—breast cancer	0.000266	0.000286	CcSEcCtD
Milnacipran—Vomiting—Mitoxantrone—breast cancer	0.000266	0.000285	CcSEcCtD
Milnacipran—Vomiting—Irinotecan—breast cancer	0.000266	0.000285	CcSEcCtD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—COX11—breast cancer	0.000265	0.00461	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC39A7—breast cancer	0.000265	0.00461	CbGpPWpGaD
Milnacipran—Dizziness—Fluorouracil—breast cancer	0.000265	0.000284	CcSEcCtD
Milnacipran—Mediastinal disorder—Methotrexate—breast cancer	0.000265	0.000284	CcSEcCtD
Milnacipran—Rash—Mitoxantrone—breast cancer	0.000264	0.000283	CcSEcCtD
Milnacipran—Rash—Irinotecan—breast cancer	0.000264	0.000283	CcSEcCtD
Milnacipran—Dermatitis—Mitoxantrone—breast cancer	0.000264	0.000283	CcSEcCtD
Milnacipran—Dermatitis—Irinotecan—breast cancer	0.000264	0.000283	CcSEcCtD
Milnacipran—Chills—Methotrexate—breast cancer	0.000264	0.000282	CcSEcCtD
Milnacipran—Headache—Irinotecan—breast cancer	0.000262	0.000281	CcSEcCtD
Milnacipran—Headache—Mitoxantrone—breast cancer	0.000262	0.000281	CcSEcCtD
Milnacipran—Hypotension—Capecitabine—breast cancer	0.000262	0.000281	CcSEcCtD
Milnacipran—Insomnia—Docetaxel—breast cancer	0.000262	0.000281	CcSEcCtD
Milnacipran—SLC6A4—NRF2 pathway—GSTM1—breast cancer	0.000261	0.00453	CbGpPWpGaD
Milnacipran—SLC6A4—NRF2 pathway—HGF—breast cancer	0.000261	0.00453	CbGpPWpGaD
Milnacipran—Paraesthesia—Docetaxel—breast cancer	0.00026	0.000279	CcSEcCtD
Milnacipran—Erythema multiforme—Epirubicin—breast cancer	0.00026	0.000279	CcSEcCtD
Milnacipran—Vomiting—Gemcitabine—breast cancer	0.000259	0.000278	CcSEcCtD
Milnacipran—Dyspnoea—Docetaxel—breast cancer	0.000258	0.000277	CcSEcCtD
Milnacipran—Somnolence—Docetaxel—breast cancer	0.000257	0.000276	CcSEcCtD
Milnacipran—Mental disorder—Methotrexate—breast cancer	0.000257	0.000276	CcSEcCtD
Milnacipran—Rash—Gemcitabine—breast cancer	0.000257	0.000276	CcSEcCtD
Milnacipran—Dermatitis—Gemcitabine—breast cancer	0.000257	0.000275	CcSEcCtD
Milnacipran—Eye disorder—Epirubicin—breast cancer	0.000257	0.000275	CcSEcCtD
Milnacipran—SLC6A4—NRF2 pathway—NRG1—breast cancer	0.000256	0.00445	CbGpPWpGaD
Milnacipran—Malnutrition—Methotrexate—breast cancer	0.000256	0.000274	CcSEcCtD
Milnacipran—Headache—Gemcitabine—breast cancer	0.000256	0.000274	CcSEcCtD
Milnacipran—Cardiac disorder—Epirubicin—breast cancer	0.000255	0.000273	CcSEcCtD
Milnacipran—Flushing—Epirubicin—breast cancer	0.000255	0.000273	CcSEcCtD
Milnacipran—Vomiting—Fluorouracil—breast cancer	0.000255	0.000273	CcSEcCtD
Milnacipran—Dyspepsia—Docetaxel—breast cancer	0.000255	0.000273	CcSEcCtD
Milnacipran—Hepatitis—Doxorubicin—breast cancer	0.000254	0.000273	CcSEcCtD
Milnacipran—Insomnia—Capecitabine—breast cancer	0.000254	0.000272	CcSEcCtD
Milnacipran—Hypoaesthesia—Doxorubicin—breast cancer	0.000253	0.000271	CcSEcCtD
Milnacipran—Rash—Fluorouracil—breast cancer	0.000253	0.000271	CcSEcCtD
Milnacipran—Dermatitis—Fluorouracil—breast cancer	0.000253	0.000271	CcSEcCtD
Milnacipran—Paraesthesia—Capecitabine—breast cancer	0.000252	0.00027	CcSEcCtD
Milnacipran—Decreased appetite—Docetaxel—breast cancer	0.000252	0.00027	CcSEcCtD
Milnacipran—Hypersensitivity—Paclitaxel—breast cancer	0.000252	0.00027	CcSEcCtD
Milnacipran—Headache—Fluorouracil—breast cancer	0.000251	0.000269	CcSEcCtD
Milnacipran—Urinary tract disorder—Doxorubicin—breast cancer	0.000251	0.000269	CcSEcCtD
Milnacipran—Oedema peripheral—Doxorubicin—breast cancer	0.000251	0.000269	CcSEcCtD
Milnacipran—Dysgeusia—Methotrexate—breast cancer	0.00025	0.000268	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Docetaxel—breast cancer	0.00025	0.000268	CcSEcCtD
Milnacipran—Connective tissue disorder—Doxorubicin—breast cancer	0.00025	0.000268	CcSEcCtD
Milnacipran—Dyspnoea—Capecitabine—breast cancer	0.00025	0.000268	CcSEcCtD
Milnacipran—Fatigue—Docetaxel—breast cancer	0.00025	0.000268	CcSEcCtD
Milnacipran—Angiopathy—Epirubicin—breast cancer	0.000249	0.000267	CcSEcCtD
Milnacipran—Urethral disorder—Doxorubicin—breast cancer	0.000249	0.000267	CcSEcCtD
Milnacipran—Nausea—Mitoxantrone—breast cancer	0.000249	0.000267	CcSEcCtD
Milnacipran—Nausea—Irinotecan—breast cancer	0.000249	0.000267	CcSEcCtD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—HES1—breast cancer	0.000249	0.00432	CbGpPWpGaD
Milnacipran—Mediastinal disorder—Epirubicin—breast cancer	0.000248	0.000266	CcSEcCtD
Milnacipran—Constipation—Docetaxel—breast cancer	0.000248	0.000265	CcSEcCtD
Milnacipran—Dyspepsia—Capecitabine—breast cancer	0.000247	0.000264	CcSEcCtD
Milnacipran—Chills—Epirubicin—breast cancer	0.000247	0.000264	CcSEcCtD
Milnacipran—Asthenia—Paclitaxel—breast cancer	0.000245	0.000263	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—EGR1—breast cancer	0.000245	0.00425	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—TGFBR2—breast cancer	0.000244	0.00424	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—GSTP1—breast cancer	0.000244	0.00424	CbGpPWpGaD
Milnacipran—Decreased appetite—Capecitabine—breast cancer	0.000244	0.000261	CcSEcCtD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC22A18—breast cancer	0.000243	0.00422	CbGpPWpGaD
Milnacipran—Nausea—Gemcitabine—breast cancer	0.000242	0.00026	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Capecitabine—breast cancer	0.000242	0.000259	CcSEcCtD
Milnacipran—Fatigue—Capecitabine—breast cancer	0.000242	0.000259	CcSEcCtD
Milnacipran—Pruritus—Paclitaxel—breast cancer	0.000242	0.000259	CcSEcCtD
Milnacipran—Vision blurred—Methotrexate—breast cancer	0.000241	0.000258	CcSEcCtD
Milnacipran—Mental disorder—Epirubicin—breast cancer	0.000241	0.000258	CcSEcCtD
Milnacipran—SLC6A2—NRF2 pathway—HMOX1—breast cancer	0.000241	0.00418	CbGpPWpGaD
Milnacipran—Erythema multiforme—Doxorubicin—breast cancer	0.00024	0.000258	CcSEcCtD
Milnacipran—Constipation—Capecitabine—breast cancer	0.00024	0.000257	CcSEcCtD
Milnacipran—Malnutrition—Epirubicin—breast cancer	0.000239	0.000256	CcSEcCtD
Milnacipran—Nausea—Fluorouracil—breast cancer	0.000238	0.000255	CcSEcCtD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC2A2—breast cancer	0.000238	0.00414	CbGpPWpGaD
Milnacipran—Eye disorder—Doxorubicin—breast cancer	0.000238	0.000255	CcSEcCtD
Milnacipran—Gastrointestinal pain—Docetaxel—breast cancer	0.000237	0.000254	CcSEcCtD
Milnacipran—Flushing—Doxorubicin—breast cancer	0.000236	0.000253	CcSEcCtD
Milnacipran—Cardiac disorder—Doxorubicin—breast cancer	0.000236	0.000253	CcSEcCtD
Milnacipran—Flatulence—Epirubicin—breast cancer	0.000236	0.000253	CcSEcCtD
Milnacipran—Tension—Epirubicin—breast cancer	0.000235	0.000252	CcSEcCtD
Milnacipran—Dysgeusia—Epirubicin—breast cancer	0.000234	0.000251	CcSEcCtD
Milnacipran—Diarrhoea—Paclitaxel—breast cancer	0.000234	0.000251	CcSEcCtD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLCO1B1—breast cancer	0.000234	0.00406	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC2A5—breast cancer	0.000234	0.00406	CbGpPWpGaD
Milnacipran—Angiopathy—Doxorubicin—breast cancer	0.000231	0.000247	CcSEcCtD
Milnacipran—Gastrointestinal pain—Capecitabine—breast cancer	0.000229	0.000246	CcSEcCtD
Milnacipran—Mediastinal disorder—Doxorubicin—breast cancer	0.000229	0.000246	CcSEcCtD
Milnacipran—Abdominal pain—Docetaxel—breast cancer	0.000229	0.000245	CcSEcCtD
Milnacipran—Body temperature increased—Docetaxel—breast cancer	0.000229	0.000245	CcSEcCtD
Milnacipran—Leukopenia—Methotrexate—breast cancer	0.000229	0.000245	CcSEcCtD
Milnacipran—Chills—Doxorubicin—breast cancer	0.000228	0.000245	CcSEcCtD
Milnacipran—Dizziness—Paclitaxel—breast cancer	0.000226	0.000242	CcSEcCtD
Milnacipran—Vision blurred—Epirubicin—breast cancer	0.000225	0.000242	CcSEcCtD
Milnacipran—SLC6A2—NRF2 pathway—GSTM1—breast cancer	0.000224	0.0039	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—HGF—breast cancer	0.000224	0.0039	CbGpPWpGaD
Milnacipran—Mental disorder—Doxorubicin—breast cancer	0.000223	0.000239	CcSEcCtD
Milnacipran—Urticaria—Capecitabine—breast cancer	0.000223	0.000239	CcSEcCtD
Milnacipran—Body temperature increased—Capecitabine—breast cancer	0.000222	0.000238	CcSEcCtD
Milnacipran—Abdominal pain—Capecitabine—breast cancer	0.000222	0.000238	CcSEcCtD
Milnacipran—Convulsion—Methotrexate—breast cancer	0.000222	0.000237	CcSEcCtD
Milnacipran—Malnutrition—Doxorubicin—breast cancer	0.000221	0.000237	CcSEcCtD
Milnacipran—SLC6A2—NRF2 pathway—NRG1—breast cancer	0.00022	0.00382	CbGpPWpGaD
Milnacipran—Agitation—Epirubicin—breast cancer	0.00022	0.000236	CcSEcCtD
Milnacipran—Flatulence—Doxorubicin—breast cancer	0.000218	0.000234	CcSEcCtD
Milnacipran—Chest pain—Methotrexate—breast cancer	0.000218	0.000233	CcSEcCtD
Milnacipran—Tension—Doxorubicin—breast cancer	0.000217	0.000233	CcSEcCtD
Milnacipran—Vomiting—Paclitaxel—breast cancer	0.000217	0.000233	CcSEcCtD
Milnacipran—Dysgeusia—Doxorubicin—breast cancer	0.000217	0.000232	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	0.000216	0.000232	CcSEcCtD
Milnacipran—Rash—Paclitaxel—breast cancer	0.000215	0.000231	CcSEcCtD
Milnacipran—Dermatitis—Paclitaxel—breast cancer	0.000215	0.000231	CcSEcCtD
Milnacipran—Syncope—Epirubicin—breast cancer	0.000215	0.00023	CcSEcCtD
Milnacipran—Leukopenia—Epirubicin—breast cancer	0.000214	0.00023	CcSEcCtD
Milnacipran—Headache—Paclitaxel—breast cancer	0.000214	0.000229	CcSEcCtD
Milnacipran—Hypersensitivity—Docetaxel—breast cancer	0.000213	0.000229	CcSEcCtD
Milnacipran—Palpitations—Epirubicin—breast cancer	0.000211	0.000227	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—SIRT1—breast cancer	0.000211	0.00366	CbGpPWpGaD
Milnacipran—Loss of consciousness—Epirubicin—breast cancer	0.00021	0.000225	CcSEcCtD
Milnacipran—Vision blurred—Doxorubicin—breast cancer	0.000209	0.000224	CcSEcCtD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—HIF1A—breast cancer	0.000208	0.00362	CbGpPWpGaD
Milnacipran—Asthenia—Docetaxel—breast cancer	0.000208	0.000223	CcSEcCtD
Milnacipran—Convulsion—Epirubicin—breast cancer	0.000207	0.000222	CcSEcCtD
Milnacipran—Infection—Methotrexate—breast cancer	0.000207	0.000222	CcSEcCtD
Milnacipran—Hypertension—Epirubicin—breast cancer	0.000207	0.000221	CcSEcCtD
Milnacipran—Hypersensitivity—Capecitabine—breast cancer	0.000207	0.000221	CcSEcCtD
Milnacipran—Pruritus—Docetaxel—breast cancer	0.000205	0.00022	CcSEcCtD
Milnacipran—Nervous system disorder—Methotrexate—breast cancer	0.000205	0.000219	CcSEcCtD
Milnacipran—Thrombocytopenia—Methotrexate—breast cancer	0.000204	0.000219	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—TYMS—breast cancer	0.000204	0.00355	CbGpPWpGaD
Milnacipran—Chest pain—Epirubicin—breast cancer	0.000204	0.000218	CcSEcCtD
Milnacipran—Agitation—Doxorubicin—breast cancer	0.000203	0.000218	CcSEcCtD
Milnacipran—Anxiety—Epirubicin—breast cancer	0.000203	0.000218	CcSEcCtD
Milnacipran—Nausea—Paclitaxel—breast cancer	0.000203	0.000217	CcSEcCtD
Milnacipran—Skin disorder—Methotrexate—breast cancer	0.000203	0.000217	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	0.000202	0.000217	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—NCOR1—breast cancer	0.000202	0.00351	CbGpPWpGaD
Milnacipran—Hyperhidrosis—Methotrexate—breast cancer	0.000202	0.000216	CcSEcCtD
Milnacipran—Asthenia—Capecitabine—breast cancer	0.000201	0.000216	CcSEcCtD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC39A6—breast cancer	0.000201	0.00349	CbGpPWpGaD
Milnacipran—Dry mouth—Epirubicin—breast cancer	0.000199	0.000214	CcSEcCtD
Milnacipran—Anorexia—Methotrexate—breast cancer	0.000199	0.000213	CcSEcCtD
Milnacipran—Syncope—Doxorubicin—breast cancer	0.000199	0.000213	CcSEcCtD
Milnacipran—Pruritus—Capecitabine—breast cancer	0.000198	0.000213	CcSEcCtD
Milnacipran—Leukopenia—Doxorubicin—breast cancer	0.000198	0.000212	CcSEcCtD
Milnacipran—Diarrhoea—Docetaxel—breast cancer	0.000198	0.000212	CcSEcCtD
Milnacipran—Palpitations—Doxorubicin—breast cancer	0.000196	0.00021	CcSEcCtD
Milnacipran—Hypotension—Methotrexate—breast cancer	0.000195	0.000209	CcSEcCtD
Milnacipran—Loss of consciousness—Doxorubicin—breast cancer	0.000195	0.000209	CcSEcCtD
Milnacipran—Infection—Epirubicin—breast cancer	0.000194	0.000208	CcSEcCtD
Milnacipran—Shock—Epirubicin—breast cancer	0.000192	0.000206	CcSEcCtD
Milnacipran—Convulsion—Doxorubicin—breast cancer	0.000192	0.000206	CcSEcCtD
Milnacipran—Diarrhoea—Capecitabine—breast cancer	0.000192	0.000206	CcSEcCtD
Milnacipran—Nervous system disorder—Epirubicin—breast cancer	0.000192	0.000205	CcSEcCtD
Milnacipran—Dizziness—Docetaxel—breast cancer	0.000191	0.000205	CcSEcCtD
Milnacipran—Thrombocytopenia—Epirubicin—breast cancer	0.000191	0.000205	CcSEcCtD
Milnacipran—Hypertension—Doxorubicin—breast cancer	0.000191	0.000205	CcSEcCtD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—breast cancer	0.000191	0.00332	CbGpPWpGaD
Milnacipran—Tachycardia—Epirubicin—breast cancer	0.000191	0.000204	CcSEcCtD
Milnacipran—Skin disorder—Epirubicin—breast cancer	0.00019	0.000203	CcSEcCtD
Milnacipran—Hyperhidrosis—Epirubicin—breast cancer	0.000189	0.000202	CcSEcCtD
Milnacipran—Insomnia—Methotrexate—breast cancer	0.000189	0.000202	CcSEcCtD
Milnacipran—Chest pain—Doxorubicin—breast cancer	0.000188	0.000202	CcSEcCtD
Milnacipran—Anxiety—Doxorubicin—breast cancer	0.000188	0.000201	CcSEcCtD
Milnacipran—Paraesthesia—Methotrexate—breast cancer	0.000187	0.000201	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	0.000187	0.000201	CcSEcCtD
Milnacipran—Anorexia—Epirubicin—breast cancer	0.000186	0.0002	CcSEcCtD
Milnacipran—Dyspnoea—Methotrexate—breast cancer	0.000186	0.000199	CcSEcCtD
Milnacipran—Somnolence—Methotrexate—breast cancer	0.000186	0.000199	CcSEcCtD
Milnacipran—Dizziness—Capecitabine—breast cancer	0.000185	0.000199	CcSEcCtD
Milnacipran—Dry mouth—Doxorubicin—breast cancer	0.000184	0.000198	CcSEcCtD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—SLC2A1—breast cancer	0.000184	0.0032	CbGpPWpGaD
Milnacipran—Vomiting—Docetaxel—breast cancer	0.000184	0.000197	CcSEcCtD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—ATP7B—breast cancer	0.000184	0.0032	CbGpPWpGaD
Milnacipran—Dyspepsia—Methotrexate—breast cancer	0.000184	0.000197	CcSEcCtD
Milnacipran—Rash—Docetaxel—breast cancer	0.000183	0.000196	CcSEcCtD
Milnacipran—Hypotension—Epirubicin—breast cancer	0.000182	0.000196	CcSEcCtD
Milnacipran—Dermatitis—Docetaxel—breast cancer	0.000182	0.000195	CcSEcCtD
Milnacipran—Decreased appetite—Methotrexate—breast cancer	0.000181	0.000194	CcSEcCtD
Milnacipran—Headache—Docetaxel—breast cancer	0.000181	0.000194	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Methotrexate—breast cancer	0.00018	0.000193	CcSEcCtD
Milnacipran—Fatigue—Methotrexate—breast cancer	0.00018	0.000193	CcSEcCtD
Milnacipran—Infection—Doxorubicin—breast cancer	0.00018	0.000192	CcSEcCtD
Milnacipran—Vomiting—Capecitabine—breast cancer	0.000178	0.000191	CcSEcCtD
Milnacipran—Shock—Doxorubicin—breast cancer	0.000178	0.000191	CcSEcCtD
Milnacipran—Nervous system disorder—Doxorubicin—breast cancer	0.000177	0.00019	CcSEcCtD
Milnacipran—Thrombocytopenia—Doxorubicin—breast cancer	0.000177	0.00019	CcSEcCtD
Milnacipran—Rash—Capecitabine—breast cancer	0.000177	0.000189	CcSEcCtD
Milnacipran—Insomnia—Epirubicin—breast cancer	0.000177	0.000189	CcSEcCtD
Milnacipran—Dermatitis—Capecitabine—breast cancer	0.000177	0.000189	CcSEcCtD
Milnacipran—Tachycardia—Doxorubicin—breast cancer	0.000176	0.000189	CcSEcCtD
Milnacipran—Headache—Capecitabine—breast cancer	0.000176	0.000188	CcSEcCtD
Milnacipran—Skin disorder—Doxorubicin—breast cancer	0.000176	0.000188	CcSEcCtD
Milnacipran—Paraesthesia—Epirubicin—breast cancer	0.000175	0.000188	CcSEcCtD
Milnacipran—Hyperhidrosis—Doxorubicin—breast cancer	0.000175	0.000187	CcSEcCtD
Milnacipran—Dyspnoea—Epirubicin—breast cancer	0.000174	0.000187	CcSEcCtD
Milnacipran—Somnolence—Epirubicin—breast cancer	0.000174	0.000186	CcSEcCtD
Milnacipran—Anorexia—Doxorubicin—breast cancer	0.000172	0.000185	CcSEcCtD
Milnacipran—Nausea—Docetaxel—breast cancer	0.000172	0.000184	CcSEcCtD
Milnacipran—Dyspepsia—Epirubicin—breast cancer	0.000172	0.000184	CcSEcCtD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—ABCC1—breast cancer	0.000171	0.00297	CbGpPWpGaD
Milnacipran—Gastrointestinal pain—Methotrexate—breast cancer	0.000171	0.000183	CcSEcCtD
Milnacipran—Decreased appetite—Epirubicin—breast cancer	0.00017	0.000182	CcSEcCtD
Milnacipran—Hypotension—Doxorubicin—breast cancer	0.000169	0.000181	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Epirubicin—breast cancer	0.000169	0.000181	CcSEcCtD
Milnacipran—Fatigue—Epirubicin—breast cancer	0.000168	0.00018	CcSEcCtD
Milnacipran—Constipation—Epirubicin—breast cancer	0.000167	0.000179	CcSEcCtD
Milnacipran—Nausea—Capecitabine—breast cancer	0.000166	0.000178	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—LEP—breast cancer	0.000166	0.00289	CbGpPWpGaD
Milnacipran—Urticaria—Methotrexate—breast cancer	0.000166	0.000178	CcSEcCtD
Milnacipran—Body temperature increased—Methotrexate—breast cancer	0.000165	0.000177	CcSEcCtD
Milnacipran—Abdominal pain—Methotrexate—breast cancer	0.000165	0.000177	CcSEcCtD
Milnacipran—Insomnia—Doxorubicin—breast cancer	0.000163	0.000175	CcSEcCtD
Milnacipran—Paraesthesia—Doxorubicin—breast cancer	0.000162	0.000174	CcSEcCtD
Milnacipran—Dyspnoea—Doxorubicin—breast cancer	0.000161	0.000173	CcSEcCtD
Milnacipran—Somnolence—Doxorubicin—breast cancer	0.000161	0.000172	CcSEcCtD
Milnacipran—Gastrointestinal pain—Epirubicin—breast cancer	0.00016	0.000171	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—CDK4—breast cancer	0.000159	0.00277	CbGpPWpGaD
Milnacipran—Dyspepsia—Doxorubicin—breast cancer	0.000159	0.00017	CcSEcCtD
Milnacipran—Decreased appetite—Doxorubicin—breast cancer	0.000157	0.000168	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Doxorubicin—breast cancer	0.000156	0.000167	CcSEcCtD
Milnacipran—Fatigue—Doxorubicin—breast cancer	0.000156	0.000167	CcSEcCtD
Milnacipran—Urticaria—Epirubicin—breast cancer	0.000155	0.000166	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—NOS2—breast cancer	0.000155	0.00269	CbGpPWpGaD
Milnacipran—Constipation—Doxorubicin—breast cancer	0.000155	0.000166	CcSEcCtD
Milnacipran—Body temperature increased—Epirubicin—breast cancer	0.000154	0.000165	CcSEcCtD
Milnacipran—Abdominal pain—Epirubicin—breast cancer	0.000154	0.000165	CcSEcCtD
Milnacipran—Hypersensitivity—Methotrexate—breast cancer	0.000154	0.000165	CcSEcCtD
Milnacipran—Asthenia—Methotrexate—breast cancer	0.00015	0.00016	CcSEcCtD
Milnacipran—Gastrointestinal pain—Doxorubicin—breast cancer	0.000148	0.000158	CcSEcCtD
Milnacipran—Pruritus—Methotrexate—breast cancer	0.000148	0.000158	CcSEcCtD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—TUBB3—breast cancer	0.000145	0.00253	CbGpPWpGaD
Milnacipran—Hypersensitivity—Epirubicin—breast cancer	0.000144	0.000154	CcSEcCtD
Milnacipran—Urticaria—Doxorubicin—breast cancer	0.000144	0.000154	CcSEcCtD
Milnacipran—Body temperature increased—Doxorubicin—breast cancer	0.000143	0.000153	CcSEcCtD
Milnacipran—Abdominal pain—Doxorubicin—breast cancer	0.000143	0.000153	CcSEcCtD
Milnacipran—Diarrhoea—Methotrexate—breast cancer	0.000143	0.000153	CcSEcCtD
Milnacipran—Asthenia—Epirubicin—breast cancer	0.00014	0.00015	CcSEcCtD
Milnacipran—Pruritus—Epirubicin—breast cancer	0.000138	0.000148	CcSEcCtD
Milnacipran—Dizziness—Methotrexate—breast cancer	0.000138	0.000148	CcSEcCtD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—CXCL8—breast cancer	0.000135	0.00235	CbGpPWpGaD
Milnacipran—Diarrhoea—Epirubicin—breast cancer	0.000134	0.000143	CcSEcCtD
Milnacipran—Hypersensitivity—Doxorubicin—breast cancer	0.000133	0.000143	CcSEcCtD
Milnacipran—Vomiting—Methotrexate—breast cancer	0.000133	0.000142	CcSEcCtD
Milnacipran—Rash—Methotrexate—breast cancer	0.000132	0.000141	CcSEcCtD
Milnacipran—Dermatitis—Methotrexate—breast cancer	0.000131	0.000141	CcSEcCtD
Milnacipran—Headache—Methotrexate—breast cancer	0.000131	0.00014	CcSEcCtD
Milnacipran—SLC6A4—Circadian rythm related genes—SERPINE1—breast cancer	0.00013	0.00226	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—IL1B—breast cancer	0.00013	0.00225	CbGpPWpGaD
Milnacipran—Asthenia—Doxorubicin—breast cancer	0.00013	0.000139	CcSEcCtD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—CASP3—breast cancer	0.000129	0.00225	CbGpPWpGaD
Milnacipran—Dizziness—Epirubicin—breast cancer	0.000129	0.000138	CcSEcCtD
Milnacipran—Pruritus—Doxorubicin—breast cancer	0.000128	0.000137	CcSEcCtD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—JUN—breast cancer	0.000126	0.00218	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—breast cancer	0.000125	0.00217	CbGpPWpGaD
Milnacipran—Vomiting—Epirubicin—breast cancer	0.000124	0.000133	CcSEcCtD
Milnacipran—Nausea—Methotrexate—breast cancer	0.000124	0.000133	CcSEcCtD
Milnacipran—Diarrhoea—Doxorubicin—breast cancer	0.000124	0.000133	CcSEcCtD
Milnacipran—Rash—Epirubicin—breast cancer	0.000123	0.000132	CcSEcCtD
Milnacipran—Dermatitis—Epirubicin—breast cancer	0.000123	0.000132	CcSEcCtD
Milnacipran—Headache—Epirubicin—breast cancer	0.000122	0.000131	CcSEcCtD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC2A2—breast cancer	0.000121	0.0021	CbGpPWpGaD
Milnacipran—Dizziness—Doxorubicin—breast cancer	0.000119	0.000128	CcSEcCtD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—ABCG2—breast cancer	0.000118	0.00206	CbGpPWpGaD
Milnacipran—Nausea—Epirubicin—breast cancer	0.000116	0.000124	CcSEcCtD
Milnacipran—Vomiting—Doxorubicin—breast cancer	0.000115	0.000123	CcSEcCtD
Milnacipran—Rash—Doxorubicin—breast cancer	0.000114	0.000122	CcSEcCtD
Milnacipran—Dermatitis—Doxorubicin—breast cancer	0.000114	0.000122	CcSEcCtD
Milnacipran—Headache—Doxorubicin—breast cancer	0.000113	0.000121	CcSEcCtD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—VEGFA—breast cancer	0.00011	0.00191	CbGpPWpGaD
Milnacipran—Nausea—Doxorubicin—breast cancer	0.000107	0.000115	CcSEcCtD
Milnacipran—SLC6A4—NRF2 pathway—TGFB1—breast cancer	0.000106	0.00185	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—TFRC—breast cancer	0.000106	0.00184	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—JUN—breast cancer	0.000103	0.00178	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—NCOA2—breast cancer	0.000102	0.00177	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—PTEN—breast cancer	9.92e-05	0.00172	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—MAPK8—breast cancer	9.71e-05	0.00169	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC5A5—breast cancer	9.7e-05	0.00169	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—TNF—breast cancer	9.41e-05	0.00164	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—SLC2A1—breast cancer	9.37e-05	0.00163	CbGpPWpGaD
Milnacipran—SLC6A2—NRF2 pathway—TGFB1—breast cancer	9.14e-05	0.00159	CbGpPWpGaD
Milnacipran—SLC6A2—SLC-mediated transmembrane transport—ALB—breast cancer	9.1e-05	0.00158	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—NCOA1—breast cancer	8.57e-05	0.00149	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—PLG—breast cancer	8.35e-05	0.00145	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—HMOX1—breast cancer	7.7e-05	0.00134	CbGpPWpGaD
Milnacipran—SLC6A4—SIDS Susceptibility Pathways—IL6—breast cancer	7.59e-05	0.00132	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—ABCB1—breast cancer	7.4e-05	0.00129	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—TP53—breast cancer	6.77e-05	0.00118	CbGpPWpGaD
Milnacipran—SLC6A4—Circadian rythm related genes—IL6—breast cancer	6.2e-05	0.00108	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—ALB—breast cancer	4.63e-05	0.000804	CbGpPWpGaD
Milnacipran—SLC6A2—Transmembrane transport of small molecules—RAF1—breast cancer	4.18e-05	0.000727	CbGpPWpGaD
